8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection (FLUCOP)
Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,
Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease.Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the ...
Voir le projet
26
Participants partenaires
TERMINÉ
Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure (EDUFLUVAC)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,
"As current influenza vaccines only afford limited protection against seasonal as well as pandemic influenza, and require regular updating, the development of a “universal” influenza vaccine that can provide broad coverage against different strains within a subtype or even across subtypes has become a key health care priority in both industrialized and low and middle income countries. EDUFLUVAC ai ...
Voir le projet
9
Participants partenaires
TERMINÉ
A Multi-Stage Malaria Vaccine (MultiMalVax)
Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,
A highly effective malaria vaccine is a major goal of global health research and will likely require a multi-stage product. MultiMalVax will develop a highly effective multi-stage malaria vaccine to the point of proof-of-concept phase II testing in Europe, prior to trials in malaria-endemic areas.Remarkable recent advances in vaccine design for all four stages of the P. falciparum parasite’s life- ...
Voir le projet
6
Participants partenaires
TERMINÉ
Innovation Partnership for a Roadmap on Vaccines in Europe (IPROVE)
Date du début: 1 déc. 2013, Date de fin: 31 mars 2016,
Under the leadership of the major Europe-based vaccine industry players, IPROVE (Innovation Partnership for a Roadmap on Vaccines in Europe) will produce a comprehensive roadmap on the future of vaccine R&D, production and delivery in the EU. IPROVE aims to drive current EU research efforts towards the establishment of a clear vision of the priority innovations and technologies necessary to addres ...
Voir le projet
5
Participants partenaires
TERMINÉ
European Network of Vaccine Development and Research (TRANSVAC)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2013,
"The TRANSVAC infrastructure will accelerate the pharmaceutical and clinical development of promising vaccine candidates by bringing the gap between academic research and clinical trials through carefully managing the advancement of promising vaccine candidates from preclinical animal models to early proof-of-principle studies in humans. Although expertise already exists within Europe spanning dif ...
Voir le projet
18
Participants partenaires
TERMINÉ
Initiative on Optimizing Malaria Vaccine Lab Assays Evaluation (OPTIMALVAC)
Date du début: 1 avr. 2009, Date de fin: 31 mars 2012,
"A broad-range of candidate malaria vaccines derived from diverse novel technologies have resulted from the multiple approaches being taken by different groups in developing malaria vaccines. The majority of the candidates are recombinant proteins based on complex native antigens found on the surface of the parasite. Vaccine potential of these parasite surface antigens is often supported by epidem ...
Voir le projet
14
Participants partenaires
TERMINÉ
"Optimisation of the development of Poverty-Related-Diseases (PRD) vaccines by a transversal approach, addressing common gaps and challenges." (INYVAX)
Date du début: 1 févr. 2009, Date de fin: 31 janv. 2012,
"A number of new vaccines are being developed against Poverty-Related infectious diseases of major public health importance at a global level. The development of all those vaccines is facing the same kind of challenges and gaps, which still prevent 1) the establishment of readily accessible formulation and scale-up process development capacity for neglected diseases vaccines. 2) the establishment ...
Voir le projet
10
Participants partenaires
TERMINÉ
Platform for the Harmonization of Vaccine Adjuvant Testing (PHARVAT)
Date du début: 1 nov. 2009, Date de fin: 31 oct. 2011,
"Adjuvants are critical to the quality and magnitude of immune responses generated by PRD vaccines. However, vaccine development is hampered by lack of access to appropriate adjuvants. This is partly because adjuvants are developed in many organizations, with individual models and protocols that have been established independently. The resulting data on adjuvants are only rarely directly comparabl ...
Voir le projet